It was announced this week that Kite Pharma Inc., a subsidiary of Gilead Sciences, has entered into a collaboration with pharma giant Pfizer to evaluate a combination of its CAR-T therapy Yescarta that was recently approved with Pfizer’s utomilumab. Utomilumab is a 4-1BB agonist that is used to treat refractory large B-cell lymphoma. Yescarta was … Continue reading “Gilead Sciences Will Collaborate with Pfizer Over This Therapy”
Tag: yescarta
Biotech & Pharma
Gilead Shares Move Higher After FDA Approves its Cancer Drug
Gilead made an excellent move acquiring Kite Pharma because a drug that Kite developed has…
October 19, 2017